Gilead Sciences Buy or Sell Recommendation

Macroaxis provides Gilead Sciences Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Gilead Sciences positions. The advice algorithm takes into account all of Gilead Sciences Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Gilead Sciences buy-and-hold prospective. Please also check Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice
Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Gilead Sciences Inc is 'Hold'.
For the selected time horizon Gilead Sciences Inc has a risk adjusted performance of 0.0397, jensen alpha of 0.0311, total risk alpha of (0.05), sortino ratio of (0.03) and treynor ratio of 0.2737
Macroaxis provides unbiased buy or sell recommendations on Gilead Sciences that should be used to complement current analysts and expert consensus on Gilead Sciences. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Gilead Sciences Inc is not overpriced, please check out all Gilead Sciences fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Given that Gilead Sciences has Number of Shares Shorted of 15.82 M, we strongly advise you confirm Gilead Sciences market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return0.05Value At Risk-0.9595
Potential Upside1.3132Standard Deviation0.6985
 Return Density 
Benchmark  Embed    Distribution 

Institutional Investors

Security TypeSharesValue
Bank Of MontrealCommon Shares2.5 M171.6 M
Candriam Luxembourg ScaCommon Shares1.5 M103.1 M
Nationwide Fund AdvisorsCommon Shares1.1 M78 M
Chevy Chase Trust Holdings IncCommon Shares1.1 M76.9 M
Retirement Systems Of AlabamaCommon Shares992.2 K67.4 M
National Pension ServiceCommon Shares893.8 K60.4 M
Antipodes Partners LtdCommon Shares781.4 K55.6 M

Gilead Sciences Greeks

Alpha over NYSE
= 0.03 
βBeta against NYSE= 0.15 
Overall volatility
= 0.70 
 IrInformation ratio =(0.03) 

Gilead Sciences Volatility Alert

Gilead Sciences Inc exhibits relatively low volatility with skewness of 0.24 and kurtosis of 0.27. However, we advice investors to further investigate Gilead Sciences Inc to make sure all market statistics is disseminated and is consistent with investors' estimations about Gilead Sciences upside potential.
 Better Than Average     
 Worse Than Average Compare Gilead Sciences to competition
FundamentalsGilead SciencesPeer Average
Return On Equity0.85 % (15.17) %
Return On Asset0.22 % (15.64) %
Profit Margin0.48 % (5.50) %
Operating Margin60.93 % (10.91) %
Current Valuation6.82 B152.14 B
Shares Outstanding1.56 B1.43 B
Shares Owned by Insiders0.60 % 6.91 %
Shares Owned by Institutions83.40 % 18.37 %
Number of Shares Shorted15.82 M3.24 M
Price to Earning6.77 times40.69 times
Price to Book5.75 times14.44 times
Price to Sales3.06 times17.81 times
Revenue466.79 M9.85 B
Gross Profit397.07 M21.75 B
EBITDA19.22 B1.41 B
Net Income72.1 M517.71 M
Cash and Equivalents616.93 M3.89 B
Cash per Share9.31 times5.17 times
Total Debt595.47 M7.36 B
Debt to Equity1.56 times0.72 times
Current Ratio1.94 times3.30 times
Book Value Per Share14.36 times13.64 times
Cash Flow from Operations74.41 M1.25 B
Short Ratio1.65 times2.09 times
Earnings Per Share10.82 times2.30 times
Price to Earnings To Growth(2.77) times1.22 times
Number of Employees8 K10.67 K
Market Capitalization6.69 B29.78 B
Total Asset1.29 B126.86 B
Retained Earnings18.15 B38.24 B
Working Capital1.08 B3.58 B
Current Asset1.18 B36.8 B


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Exercise or conversion by Paul Carter of 2000 shares of Gilead Sciences subject to Rule 16b-3 [view details]
Risk Adjusted Performance0.0397
Market Risk Adjusted Performance0.2837
Mean Deviation0.5354
Semi Deviation0.6659
Downside Deviation0.8014
Coefficient Of Variation1381.34
Standard Deviation0.6985
Information Ratio(0.03)
Jensen Alpha0.0311
Total Risk Alpha(0.05)
Sortino Ratio(0.03)
Treynor Ratio0.2737
Maximum Drawdown1.78
Value At Risk(0.96)
Potential Upside1.31
Downside Variance0.6423
Semi Variance0.4434
Expected Short fall(0.50)

Current Valuation

Gilead Sciences Current Valuation Analysis
Gilead Sciences Inc is rated # 5 in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Pharmaceuticals And Biosciences industry is currently estimated at about 132.48 Billion. Gilead Sciences holds roughly 6.82 Billion in current valuation claiming about 5% of equities listed under Pharmaceuticals And Biosciences industry.